PT-141 (Bremelanotide)
A melanocortin receptor agonist that directly activates the CNS to increase sexual desire and function.
Community Rating
No ratings yet
Compound Profile
PT-141 (Bremelanotide)
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. PT-141 (Bremelanotide) is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Increases sexual desire and libido in men and women
- Effective for erectile dysfunction even when PDE5 inhibitors fail
- Works via CNS activation — addresses psychological component of sexual dysfunction
- PT-141 (Bremelanotide) is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Increases sexual desire and libido in men and women
- Effective for erectile dysfunction even when PDE5 inhibitors fail
- Works via CNS activation — addresses psychological component of sexual dysfunction
- FDA-approved (Vyleesi) for HSDD in premenopausal women
In Plain English
Simple summaryPT-141 started as a side effect. Researchers testing Melanotan II for tanning at the University of Arizona noticed it was triggering spontaneous erections and strong sexual arousal -- and pivoted the research program. PT-141 is the refined result: stripped of the tanning action, targeting the melanocortin-4 receptor (MC4R) in the brain that governs sexual arousal. It became Vyleesi, FDA-approved for hypoactive sexual desire disorder in premenopausal women. For men it's used off-label for erectile dysfunction, acting centrally on the brain rather than peripherally on blood vessels like PDE5 inhibitors (Viagra, Cialis) do.
- Increases sexual desire and libido in men and women
- Effective for erectile dysfunction even when PDE5 inhibitors fail
- Works via CNS activation — addresses psychological component of sexual dysfunction
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is PT-141 (Bremelanotide)?
Tap any underlined term for an instant definition.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II, developed by Palatin Technologies. Unlike traditional erectile dysfunction drugs that work by increasing blood flow to the genitals, PT-141 works by directly activating melanocortin receptors (MC3R and MC4R) in the central nervous system, specifically in the hypothalamus, to increase sexual motivation and desire. This central mechanism of action makes it effective for both men and women. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first non-hormonal treatment for female sexual dysfunction.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on PT-141 (Bremelanotide). See all Sexual Health peptides for comparison.
Common Stacks
PT-141 (Bremelanotide) is frequently combined with the following peptides for synergistic effects. Click any peptide to compare profiles before deciding.
Both are melanocortin-based sexual function compounds - PT-141 is the selective successor to Melanotan II for sexual arousal without tanning.
Oxytocin's pro-bonding and anxiety-reducing effects complement PT-141's physical arousal mechanism for a comprehensive intimacy protocol.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Typical research dosing: 0.5–2 mg subcutaneously, 1–2 hours before sexual activity. Start with 0.5 mg to assess tolerance. Maximum recommended dose is 2 mg. Do not use more than once per 72 hours due to prolonged action.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Reconstitute with bacteriostatic water, administer subcutaneously (abdomen or thigh). Administer 1–2 hours before desired effect. Pre-medicate with an antiemetic (e.g., ondansetron) if nausea is a concern. Lying down after injection can reduce nausea. Avoid high-fat meals before use.
What the research doesn't show
Nausea is common enough with PT-141 that it's one of the main reasons for discontinuation in clinical trials. Blood pressure transient changes (elevation) also occur. Pre-dosing with antiemetics and staying well-hydrated are common mitigation strategies in clinical protocols.
Research Video
Medical Expert Videos
Physicians, researchers, and pharmacologists explain PT-141 (Bremelanotide), covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
PT-141 (Bremelanotide) has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: increases sexual desire and libido in men and women.
The most commonly reported side effect in research subjects is nausea. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
Research Articles
- PT-141 (Bremelanotide): The Peptide That Works on the Brain, Not the Blood Vessels7 min read
- PT-141 (Bremelanotide) Dosage Guide: Reconstitution and Research Protocol6 min read
How It Compares
Viagra and Cialis work peripherally -- they enhance blood flow to the genitals when arousal already exists. PT-141 works centrally -- it initiates arousal at the brain level. They're often complementary: PT-141 for desire, PDE5 inhibitors for the peripheral vascular response. PT-141's main drawback is nausea, which occurs in a significant proportion of users.
Compare PT-141 (Bremelanotide) side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.